223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

Jiaqiong Wang; Russ Kuker; Aldo Serafini

doi:10.1097/RLU.0000000000003168

²²³Ra-Dichloride Response Evaluation Using ¹⁸F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

Jiaqiong Wang, Russ Kuker, Aldo Serafini

Radiology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

Original language	English (US)
Pages (from-to)	e486-e488
Journal	Clinical nuclear medicine
Volume	45
Issue number	11
DOIs	https://doi.org/10.1097/RLU.0000000000003168
State	Published - Nov 1 2020

Keywords

F-fluciclovine PET/CT
Ra-dichloride
Tc-MDP
bone scan
prostate cancer

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/RLU.0000000000003168

Cite this

@article{86ae1b26c1a64b6aad79a6d32090cbdf,

title = "223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer",

abstract = "A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued. ",

keywords = "F-fluciclovine PET/CT, Ra-dichloride, Tc-MDP, bone scan, prostate cancer",

author = "Jiaqiong Wang and Russ Kuker and Aldo Serafini",

year = "2020",

month = nov,

day = "1",

doi = "10.1097/RLU.0000000000003168",

language = "English (US)",

volume = "45",

pages = "e486--e488",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

AU - Wang, Jiaqiong

AU - Kuker, Russ

AU - Serafini, Aldo

PY - 2020/11/1

Y1 - 2020/11/1

N2 - A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

AB - A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

KW - F-fluciclovine PET/CT

KW - Ra-dichloride

KW - Tc-MDP

KW - bone scan

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85092680092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092680092&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000003168

DO - 10.1097/RLU.0000000000003168

M3 - Article

C2 - 32657864

AN - SCOPUS:85092680092

VL - 45

SP - e486-e488

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 11

ER -